Top: Illustration of formation of solid implant by phase inversion and drug release via diffusion and implant degradation. Bottom: Modeling predicted a 2 mL and 3 mL injection can sustain plasma concentrations of CAB above levels needed for protection against HIV in humans for 4 and 5 months, respectively.

Isabella Young, PhD student in Dr. Rahima Benhabbour's lab (top) and Ivana Massud, PhD, senior research associate at the CDC (bottom), were co-first authors.